By The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.
The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant
Scientist researcher chemist doctor working with transparent glassware mixing liquid solution during microbiology experiment in hospital laboratory. Medical equipment on table. Medicine concept
Comments